Skip to main content
CSL Reaffirms Commitment to Manufacture AstraZeneca COVID Vaccine into 2022

CSL Reaffirms Commitment to Manufacture AstraZeneca COVID Vaccine into 2022

Melbourne, Australia:  CSL is committed to the manufacture of approximately 50 million doses of the AstraZeneca COVID-19 vaccine, Vaxzevria. Already over 20 million doses have been produced to protect Australians and those in the Asia Pacific region, and it is expected that the remaining production will be completed early next year.

As CSL Chair Brian McNamee AO said at the Annual General Meeting this week: “We are pleased to say that the Australian Government and AstraZeneca trusted us as their partners to help the country respond to the emerging crisis through the most effective solution available: vaccination.”

CSL and Seqirus are proud of the role they have played in providing Australia with onshore vaccine manufacturing capability throughout the pandemic.

### - ENDS - ###

About CSL

CSL (ASX:CSL; USOTC:CSLLY) is a leading global biotechnology company with a dynamic portfolio of life-saving medicines, including those that treat haemophilia and immune deficiencies, as well as vaccines to prevent influenza. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our two businesses, CSL Behring and Seqirus – provides life-saving products to more than 70 countries and employs more than 25,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. For inspiring stories about the promise of biotechnology, visit Vita at and follow us on

For more information about CSL Limited, visit              

Get our latest news releases in your inbox
* Required Fields